Peptides DB
Research-centric peptide and protocol reference hub
Study 13 of 17HMG (Human Menopausal Gonadotropin) literaturebiorxiv-preprint · Observational2023

Highly purified-hMG versus rFSH in ovarian hyperstimulation in women undergoing elective fertility preservation

In women undergoing elective fertility preservation, rFSH appears to yield more oocytes than hp-hMG, but the implications of these findings should be interpreted with caution due to potential confounding factors.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the hmg (human menopausal gonadotropin) corpus
0
Preclinical
13
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This study compared the effects of highly purified human menopausal gonadotropin (hp-hMG) and recombinant FSH (rFSH) on ovarian response in 456 women undergoing elective fertility preservation. The findings indicated that rFSH resulted in a higher number of retrieved and mature oocytes compared to hp-hMG. No therapeutic claims are made.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Peak estradiol level was significantly lower in the rFSH group (2547.18±1648.21 pg/mL) than in the hp-hMG group (3468.02±2497.69 pg/mL, P<0.001).2023

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p><bold>Purpose:</bold> To compare recombinant FSH (rFSH) with highly purified-human menopausal gonadotrophin (hp-hMG) on ovarian response in women undergoing elective fertility preservation (FP). <bold>Methods:</bold> This retrospective study included 456 women who underwent elective FP with gonadotropin-releasing hormone (GnRH) antagonist or progestin-primed ovarian stimulation (PPOS) protocols between 01/2017-12/2021. Three-hundred and forty-one women were stimulated with rFSH and 115 with hp-hMG, and the ovarian stimulation outcomes were compared between the two groups. A multivariate linear regression analysis assessed the impact of age, basal FSH level, antral follicle count, and protocol type on the ovarian stimulation outcomes. <bold>Results: </bold>Women in the rFSH group were significantly younger, and their antral follicle count was significantly higher than those in the hp-hMG group (35.50±2.12 vs. 35.99±2.13 years,<italic> P </italic>= 0.034 and 13.76±6.08 vs. 11.84±6.06, <italic>P</italic> = 0.002). There were no significant group differences in the amount (<italic>P</italic> = 0.645) and duration (<italic>P</italic> = 0.265) of FSH stimulation. The peak estradiol level was significantly lower for the rFSH group compared to the hp-hMG group (2547.18±1648.21 pg/mL vs. 3468.02±2497.69 pg/mL, <italic>P</italic> < 0.001), while peak progesterone level was significantly higher (1.33±0.75 ng/mL vs. 1.01±0.52 ng/mL, <italic>P</italic> = 0.001). The numbers of retrieved and MII oocytes were significantly higher for the rFSH group compared with the hp-hMG group (16.82±10.95 vs. 13.25±9.66, <italic>P</italic> = 0.02, and 13.22±9.13 vs. 9.76±7.11, <italic>P</italic> = 0.005), while the maturity rates were comparable (<italic>P</italic> = 0.103). <bold>Conclusion:</bold> rFSH was demonstrated to have superior oocyte yield compared to hp-hMG in ovarian hyperstimulation for women undergoing elective FP.</p>

Elsewhere in the HMG (Human Menopausal Gonadotropin) corpus

BComparison between the efficacy of short and long GnRH-a protocols as a clinical outcome for viable pregnancies in women undergoing IVF/ICSI Cycles.biorxiv-preprint · 2021 · Clinical pregnancy rates: LAP 33.12% vs SAP 28.23%, p=0.001.HumanBRecombinant Follicular Stimulating Hormone Plus Recombinant Luteinizing Hormone Versus Human Menopausal Gonadotropins- Does the Source of LH Bioactivity Affect Ovarian Stimulation Outcome?biorxiv-preprint · 2021 · Mean number of mature oocytes retrieved: 10 ± 5.8 in rFSH+rLH vs 8.3 ± 4.6 in HP-hMG, p=0.01.HumanBUsing Letrozole Cotreatment With Progestin-Primed Ovarian Stimulation In Women With Polycystic Ovary Syndrome Treated For IVFbiorxiv-preprint · 2021 · 42.22% implantation rate in letrozole group vs. 34.69% in control group, p<0.05HumanBEvaluation of assisted reproductive technology treatment outcomes based on stimulation dosages and anti-Mullerian hormone levelsbiorxiv-preprint · 2022 · Not reported in abstract.HumanBA FSH-secreting pituitary adenoma discovered after ovarian hyperstimulation syndrome: a case report, illustrating pitfalls in the interpretation of serum FSH levelsbiorxiv-preprint · 2024 · Estradiol elevated at 737 pg/ml.HumanCErzhi Tiangui formula ameliorates ovarian aging by enhancing antioxidant defense via Nrf2/HO-1 signaling.europepmc · 2026 · Not reported in abstract.Animal